6-Alkyl Naphthamide Compounds for Ocular Hypertension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly primary and secondary forms, face challenges in effectively reducing intraocular pressure due to obstruction of aqueous humor outflow, with existing ocular hypotensive agents having limitations in efficacy and comfort for patients.
Innovation Solution
Development of well-defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds that can be administered topically to reduce intraocular pressure by facilitating the outflow of aqueous humor, with specific structures and pharmaceutical compositions designed for ocular hypertension treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional β-adrenoreceptor antagonists are used to treat glaucoma, then intraocular pressure can be reduced, but patient comfort and tolerability are compromised
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of naphthamide compounds (changing R1, R2, R3, R4 substituents and n values) to optimize the balance between IOP reduction efficacy and ocular tolerability, creating derivatives with improved safety profiles while maintaining therapeutic effect
2Reliability
If existing ocular hypotensive agents are administered, then some intraocular pressure reduction is achieved, but efficacy is insufficient for many patients
Solution Approach 1:
The patent employs composite material principles by designing molecules that combine the naphthamide core structure with various substituent groups (alkyl, hydroxyalkyl, aryl, heteroaryl combinations), creating composite molecular structures that achieve superior IOP reduction compared to single-structure agents
3Object-affected harmful factors
If topical administration is used for ocular hypotensive agents, then patient comfort is improved, but drug delivery efficacy is reduced
Solution Approach 1:
The patent applies local quality principles by designing compounds with specific local molecular characteristics (substituent positions and types at specific locations on the naphthamide core) that enhance ocular surface compatibility while maintaining or improving intraocular penetration and therapeutic effect
Data Source
AI summary
This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension.